On May 2, 2022, UAEM sent a letter to Ron Klain, White House Chief of Staff. The letter requests assurance that White House officials with financial conflicts of interest recuse themselves from the review of the petition asking the government to march-in and exercise other rights to the life-saving prostate cancer drug Xtandi (enzalutamide) originally developed with funds from the National Institutes of Health (NIH) and Department of Defense (DOD) at the University of California, Los Angeles (UCLA). Read the full text here.
Continue reading
NAVYA DASARI
NEELU PALETI
UAEM has sent an open letter to The Hon. Robert M. Califf, the newly appointed U.S. Food and Drug Administration (FDA) Commissioner calling his leadership to attend with real urgency to the significant but so far underserved issue of clinical trial registration and results reporting.
Read the full letter here.
Continue reading
